Before your interview: know your own resume
Anything on your resume can become an interview question. Be ready to explain every internship, certificate, project, instrument, software skill, clinical-trial phase or production/QC activity you mention: what it means, what you personally did, why you did it, the result and what you learned. Clearly distinguish observation, simulation, supervised practice and independent work. A certificate demonstrates training, not automatic practical competence. Adapt the examples to your own experience; never invent achievements.
Guide scope: Entry-level pharmaceutical submissions, CMC, labelling and lifecycle work across clearly labelled markets.
Practise each answer aloud, then explain it in your own words. These are original preparation questions and example approaches, not a verified employer question paper or a promise of selection. Confirm current role-specific requirements with authorised sources.
Jump to a section
Resume, internships, certificates and HR
Question 1 / 101
1. Tell me about yourself.
Give a 60–90 second introduction: your qualification, one relevant experience, a skill you can demonstrate and why this role fits. A useful structure is: 'I studied …, worked on …, personally handled …, and learned …'. Replace each example with truthful details; avoid reciting your entire resume.
Question 2 / 101
2. Walk me through the parts of your resume most relevant to this job.
Select two or three relevant experiences and explain the link to the job description. For each, state the setting, your responsibility and a concrete output. Clearly identify classroom, simulated and workplace experience. Expect follow-up questions about every technical term you mention.
Question 3 / 101
3. What exactly did you do during your internship?
Explain the department, duration, supervisor and tasks you actually performed. Separate observations from hands-on work. Describe one activity from input to output, including checks and escalation. If you only observed a process, say so and explain what you understood rather than claiming independent responsibility.
Question 4 / 101
4. Which internship activity could you explain from beginning to end?
Choose one real activity. Explain its purpose, required input, sequence, safety or quality checks, documentation and the person who approved the result. Be ready to explain why each step existed and what would happen if it was missed. Do not disclose confidential patient or company details.
Question 5 / 101
5. What did your certificate teach you, and what did you practise?
Name the course, provider, completion date and main modules. Then distinguish lectures, assessed exercises and practical tasks. For example: 'I completed the theory module and practised with a training dataset; I have not used the production system.' Explain one concept well instead of listing certificates without understanding them.
Question 6 / 101
6. Explain the objective of a project on your resume.
State the problem, why it mattered, the objective and your own contribution. Explain the setting and limitations before describing results. If the work was simulated or academic, say so. Do not imply that a classroom exercise produced real patient, manufacturing or commercial outcomes.
Question 7 / 101
7. How did you choose your project's method?
Explain why the method addressed the objective, what alternatives you considered and which constraints mattered. Identify the protocol, reference or supervisor input used. Discuss one limitation honestly. A strong answer shows reasoning; naming a technique without explaining its purpose does not demonstrate competence.
Question 8 / 101
8. How did you check the accuracy of your project results?
Describe the real checks you performed: source comparison, calculations, controls, peer review or supervisor verification as applicable. Explain how you handled missing information and discrepancies. Avoid saying that the result was 100% accurate unless you can define and substantiate that claim.
Question 9 / 101
9. Your resume mentions an improvement percentage. How was it calculated?
State the baseline, final value, denominator and time period. Explain whether the result is an absolute difference or a relative change, and identify your contribution. If you cannot reconstruct a number from authorised evidence, correct the claim rather than invent a calculation during the interview.
Question 10 / 101
10. Which instrument or software function have you personally used?
Name the specific task and your level of access or supervision. Walk through the input, action, output and checks. Separate familiarity with terminology from hands-on competence. Be prepared for a practical demonstration using nonconfidential training material and do not claim certification or administrator access you do not have.
Question 11 / 101
11. Which academic subject is most relevant to this role?
Choose a subject you understand and connect one concept to a real role activity. Explain the concept in simple language, then give an example and limitation. Revise any subjects or clinical-trial phases you highlight on your resume; mentioning a topic invites deeper questions about it.
Question 12 / 101
12. Why do you want to work in this department?
Connect your interest to actual responsibilities in the job description. Support it with a truthful course, project or work example. Explain what you want to learn and contribute. Avoid claims that the department is easy, guarantees high pay or provides a shortcut around the technical learning required.
Question 13 / 101
13. Why are you interested in this employer?
Use two current facts from the employer's own website or job description and explain their relevance to the role. Then connect your demonstrated skills to the team's work. Do not invent company rankings, employee counts, client relationships or promises about training that you have not verified.
Question 14 / 101
14. What is a strength you can demonstrate?
Choose one relevant strength and prove it with a brief example. 'I use a source-check checklist; in my project it helped me catch a date mismatch before review' is stronger than 'I never make mistakes'. State what you personally did and what evidence supports the result.
Question 15 / 101
15. What is a weakness you are working on?
Describe a genuine, manageable development area and the steps you are taking. For example: 'I used to give overly long explanations, so I practise a one-minute summary before the detail.' Explain progress without disguising a boast as a weakness or suggesting that essential safety requirements are optional.
Question 16 / 101
16. How do you explain a career gap or change of field?
Give a brief factual explanation at a level you are comfortable sharing, then discuss relevant learning and readiness for the role. You do not need to invent employment, training or personal circumstances. Connect transferable skills to the job while acknowledging the department-specific training still needed.
Question 17 / 101
17. Give an example of teamwork.
Use Situation, Task, Action and Result. Describe the shared objective, your own contribution and how you handled communication or a handoff. An academic project is a valid example when labelled accurately. Do not take credit for the whole team's work or reveal confidential information.
Question 18 / 101
18. How do you work under pressure?
Explain how you identify the highest-impact tasks, confirm priorities, work through a checklist and communicate delays early. Support the answer with a real example. Speed should not mean skipping required checks, hiding errors or working outside your training and authority.
Question 19 / 101
19. Can you work shifts, relocate or meet the joining date?
Answer honestly about your availability and constraints, then ask for the actual schedule and role expectations. Do not automatically say yes to conditions you cannot meet. You can be professional and interested while clarifying notice periods, transport arrangements or practical limitations.
Question 20 / 101
20. What would you do if you realised your resume overstated a skill?
Correct the claim promptly and explain your actual level. Offer an accurate example of what you can demonstrate and a realistic learning plan. Honesty protects both you and the employer; rehearsing an invented answer is especially risky in work involving safety, regulated records or confidential information.
Technical interview questions
Question 21 / 101
21. What is Regulatory Affairs in pharmaceuticals?
Regulatory Affairs helps a company develop, register and maintain medicines in line with the requirements of each market. The work connects scientific evidence, product information and regulatory submissions. In an interview, explain that the role continues after approval through changes, commitments and ongoing compliance.
Question 22 / 101
22. What does an entry-level Regulatory Affairs associate do?
Typical tasks include checking documents, maintaining trackers, compiling submission sections and coordinating with technical teams. An associate may also support publishing, labelling comparisons and responses to authority questions. The exact responsibilities depend on whether the team handles CMC, operations, clinical submissions or product maintenance.
Question 23 / 101
23. How is Regulatory Affairs different from Quality Assurance?
Regulatory Affairs manages the requirements and commitments associated with product authorisations. Quality Assurance oversees the quality system and controlled ways of working. They collaborate when a deviation or manufacturing change could affect a registered product. Neither function should make the other's technical decisions without the appropriate review.
Question 24 / 101
24. How is Regulatory Affairs different from Quality Control?
Quality Control generates and assesses laboratory results against approved methods and specifications. Regulatory Affairs uses approved technical information to support submissions and evaluate regulatory impact. For example, QC may investigate a test result while RA checks whether any resulting specification change needs a submission.
Question 25 / 101
25. How would you explain CDSCO and the DCGI?
CDSCO is India's Central Drugs Standard Control Organization. DCGI refers to the Drugs Controller General of India, an official role within that regulatory structure. Do not describe the two as competing agencies. For a specific application, check the relevant central and state licensing responsibilities. CDSCO reference.
Question 26 / 101
26. What is the US FDA's role in drug regulation?
The FDA regulates drugs in the United States through activities including application review, manufacturing oversight and postmarketing surveillance. An RA associate should identify the relevant centre, product type and submission pathway. A US authorisation does not automatically authorise sale in every other country. FDA reference.
Question 27 / 101
27. What is the difference between EMA and the European Commission?
EMA coordinates scientific evaluation for the EU centralised procedure. The European Commission issues the legally binding centralised marketing-authorisation decision. National competent authorities also have important roles in European regulation. Avoid saying that every European application is submitted through one identical route. EMA reference.
Question 28 / 101
28. What is ICH?
ICH develops harmonised technical guidelines for pharmaceutical development and registration. These guidelines support consistency across participating regulatory systems. ICH does not itself approve a company's medicine; implementation and legal effect depend on the relevant regulator and jurisdiction. ICH reference.
Question 29 / 101
29. What is a regulatory dossier?
A dossier is the organised information submitted to support a regulatory request. Its contents depend on the product, application and jurisdiction. Strong dossiers make it possible for a reviewer to locate evidence, understand the rationale and trace important statements back to approved supporting documents.
Question 30 / 101
30. What is the Common Technical Document?
The CTD is a harmonised structure for organising a medicinal-product registration dossier. It is a content framework, not a product approval. In an interview, connect it to consistent organisation of quality, nonclinical and clinical information rather than treating it as a single application form. ICH reference.
Question 31 / 101
31. What are the five CTD modules?
Module 1 contains region-specific administrative information; Module 2 contains summaries and overviews; Module 3 covers quality; Module 4 contains nonclinical study reports; and Module 5 contains clinical study reports. The regional requirements still determine the precise content needed for a particular application. ICH reference.
Question 32 / 101
32. Why is CTD Module 1 region-specific?
Administrative forms, legal declarations and local product information can differ between markets. A core scientific dossier therefore does not eliminate local administrative work. Before reusing Module 1, check the target authority's current requirements instead of copying the previous market's documents. ICH reference.
Question 33 / 101
33. How are Module 2 and the detailed modules related?
Module 2 summarises and interprets information supported by Modules 3, 4 and 5. A useful quality check is to compare key values and conclusions with the underlying reports. The summary should not introduce unsupported results or conceal a material limitation in the source evidence. ICH reference.
Question 34 / 101
34. What does CMC mean?
CMC means Chemistry, Manufacturing and Controls. It addresses how the product and its materials are made, characterised and controlled. RA professionals use CMC information to explain product quality and assess the regulatory implications of changes during development and after approval. FDA reference.
Question 35 / 101
35. What is eCTD?
eCTD is an electronic submission standard that organises documents and their lifecycle for regulatory review. It is more than putting PDFs in a folder. Content organisation, metadata and technical specifications must align with the version and regional implementation accepted by the receiving authority. FDA reference.
Question 36 / 101
36. How does eCTD differ from CTD?
CTD describes how dossier content is organised. eCTD adds a defined electronic structure and lifecycle approach for delivering that content. A technically valid eCTD does not guarantee scientific acceptability; the evidence inside must still be complete and appropriate for the regulatory request. FDA reference.
Question 37 / 101
37. What is an eCTD sequence?
A sequence is a submission unit within an application's electronic lifecycle, such as an initial submission or a subsequent update. It is not a CTD module. Its numbering, metadata and relationship to prior content must follow the receiving authority's current technical specifications. FDA reference.
Question 38 / 101
38. How should you choose an eCTD version?
Check the receiving authority's current supported standards and the application's lifecycle constraints. Do not assume that the newest global specification is mandatory everywhere or that a new version can be adopted midway through every existing application. Record the basis for the publishing decision. FDA reference.
Question 39 / 101
39. What is technical validation of a submission?
Technical validation checks whether the electronic package follows the authority's required technical rules. Issues may concern structure, metadata, links or document properties. Resolve errors with the publishing team and record the outcome. Passing validation is different from an authority accepting the scientific argument. FDA reference.
Question 40 / 101
40. What is a submission checklist used for?
It makes required documents, approvals and technical checks visible before dispatch. A useful checklist records applicability and evidence, not just ticks. If an item is not applicable, provide a justified rationale and the appropriate review rather than deleting the item to make the checklist appear complete.
Question 41 / 101
41. What is the purpose of a submission cover letter?
A cover letter helps orient the authority to the request, application identifiers and included information. It should be concise and consistent with the package. Use the current authority and company requirements; a cover letter cannot repair missing evidence elsewhere in a submission.
Question 42 / 101
42. What is a document cross-reference?
It points the reviewer to supporting information elsewhere in the dossier or a permitted referenced file. Check both the destination and its relevance. A functioning hyperlink is not sufficient if it opens an obsolete report or the wrong section of an otherwise correct document.
Question 43 / 101
43. What is an active pharmaceutical ingredient?
An API is the substance intended to provide a drug's pharmacological activity or another direct effect. Regulatory information must identify and control the relevant material. Distinguish the API from the finished dosage form and from ingredients used mainly to support formulation or manufacturing.
Question 44 / 101
44. What is the difference between drug substance and drug product?
Drug substance refers to the active material; drug product is the finished dosage form containing it and, where applicable, other ingredients. The distinction matters when locating manufacturing, control and stability information. One product may involve multiple substances or more complex product-specific arrangements.
Question 45 / 101
45. What is an excipient?
An excipient is a formulation ingredient other than the active ingredient, used for functions such as binding, preservation or delivery. Its suitability still matters to quality and patient safety. Do not assume that an ingredient is acceptable for every route or exposure simply because it has been used previously.
Question 46 / 101
46. What is a product specification?
A specification sets out tests, analytical procedures and acceptance criteria used to assess a material or product. It should be scientifically justified and aligned with applicable requirements. Passing specifications alone does not compensate for an uncontrolled manufacturing process or unreliable underlying data.
Question 47 / 101
47. What is a certificate of analysis?
A certificate of analysis reports identified testing information for a particular material or batch. RA may check that it matches the dossier's material, method and specification baseline. A certificate is not a substitute for the complete manufacturing and control justification where that is required.
Question 48 / 101
48. What is analytical-method validation?
It establishes, with appropriate evidence, that an analytical procedure is suitable for its intended purpose. The relevant performance characteristics depend on what the method measures and how it is used. Avoid listing every characteristic as mandatory for every analytical procedure.
Question 49 / 101
49. How is method validation different from method transfer?
Validation addresses suitability for the intended analytical purpose. Transfer addresses whether a receiving laboratory can perform the method appropriately under an agreed approach. A validated method may still need transfer activities; the regulatory and quality implications depend on the product and proposed change.
Question 50 / 101
50. What is the purpose of stability testing?
Stability studies examine how quality changes over time under relevant environmental conditions. They support matters such as drug-product shelf life, drug-substance retest period and storage conditions. The study design and interpretation should fit the product, packaging and target markets. ICH reference.
Question 51 / 101
51. How do long-term and accelerated stability studies differ?
Long-term studies follow the product under defined conditions relevant to the intended storage claim. Accelerated studies use more stressful conditions to support understanding of change. They are complementary; accelerated results alone should not be treated as an automatic replacement for all long-term data. ICH reference.
Question 52 / 101
52. What is the difference between a retest period and shelf life?
A retest period generally concerns when a drug substance should be re-examined for suitability. Shelf life concerns the period a product is expected to meet its specification under defined storage conditions. These concepts should not be interchanged when preparing dossier tables or artwork. ICH reference.
Question 53 / 101
53. What does GMP mean?
Good Manufacturing Practice refers to controls intended to ensure consistent manufacture and quality. It involves systems, facilities, people and reliable processes, not just end-product testing. For a US interview, explain that the FDA uses the term current Good Manufacturing Practice, or CGMP. FDA reference.
Question 54 / 101
54. Why is change control important to Regulatory Affairs?
It creates a structured opportunity to assess a proposed change before implementation. RA checks affected markets, dossier commitments and submission requirements while technical functions assess quality and other impacts. A change that is minor operationally can still have significant regulatory consequences.
Question 55 / 101
55. What is a US Drug Master File?
A DMF can provide confidential detailed information referenced in support of an application. FDA reviews its technical contents in the context of referencing applications. A DMF is not itself approved or disapproved and does not replace an NDA, ANDA or IND. FDA reference.
Question 56 / 101
56. What is a letter of authorisation for a DMF?
It permits FDA to refer to specified DMF information in support of an authorised party's submission. It does not automatically give that party access to the confidential contents. Check the relevant parties, scope and application details before relying on the reference. FDA reference.
Question 57 / 101
57. What is an IND in the United States?
An Investigational New Drug application supports the lawful clinical investigation of an investigational drug under the applicable US framework. It is a development-stage regulatory mechanism, not marketing approval. Relevant evidence and responsibilities depend on the product and investigation. FDA reference.
Question 58 / 101
58. What is an NDA in the United States?
A New Drug Application requests authorisation to market a drug and contains evidence supporting its proposed use and quality. Explain its purpose before discussing document structure. Do not confuse submitting an NDA with receiving an approval decision. FDA reference.
Question 59 / 101
59. What is an ANDA in the United States?
An Abbreviated New Drug Application is the pathway for eligible generic drug products. It generally relies on the reference product's established safety and effectiveness while providing the required generic-product evidence. It is not an evidence-free shortcut, and suitability must be assessed for the particular product. FDA reference.
Question 60 / 101
60. Why is an ANDA called abbreviated?
The application generally does not repeat the full nonclinical and clinical programme used to establish the reference product's safety and effectiveness. It still needs substantial quality information and applicable evidence of equivalence. Avoid claiming that every generic application needs exactly the same study design. FDA reference.
Question 61 / 101
61. What is bioequivalence?
Bioequivalence concerns comparison of relevant product performance using an accepted approach appropriate to the drug and dosage form. Pharmacokinetic studies are one approach, but requirements can be product-specific. In an interview, check the current guidance before proposing a universal design or acceptance rule. FDA reference.
Question 62 / 101
62. What is the relevance of India's New Drugs and Clinical Trials Rules?
The NDCT Rules establish requirements for relevant new drugs and clinical trials in India. For a real task, check the rules, applicable amendments and current CDSCO instructions. An older training slide or an overseas definition should not be used as the sole basis for an Indian application. CDSCO reference.
Question 63 / 101
63. What is regulatory labelling work?
It involves preparing, reviewing and maintaining required product information against the approved evidence and local requirements. RA coordinates scientific, safety, legal and operational input. It should distinguish proposed wording from approved wording and promotional material from regulated product information. EMA reference.
Question 64 / 101
64. What is an SmPC?
The Summary of Product Characteristics is EU product information for healthcare professionals, organised under defined headings. It describes the authorised product and its use. It should not be confused with the patient package leaflet or assumed to have exactly the same legal format in every market. EMA reference.
Question 65 / 101
65. What is a patient information leaflet?
It is product information intended for patients and users, with requirements depending on the jurisdiction. The content must communicate the relevant approved information clearly. Plain language does not justify changing the scientific meaning, and a leaflet is not simply a shortened advertisement. EMA reference.
Question 66 / 101
66. What should you check during an artwork review?
Check the approved text, product name, strength, dosage form, warnings, storage information and applicable identifiers against the controlled baseline. Confirm the correct market and pack version. Route visual, technical and safety matters to the qualified reviewers instead of treating RA review as a one-person release process.
Question 67 / 101
67. What is a postapproval change?
It is a change affecting an already authorised product or its registered particulars. The required route depends on its nature, risk and jurisdiction. Assessment may lead to prior approval, notification or another mechanism; never apply one market's classification automatically to all others. EMA reference.
Question 68 / 101
68. What does a Type II variation mean in the EU?
It is a major variation, distinct from an extension, that may significantly affect quality, safety or efficacy. Use the current classification framework to assess a specific change. The words minor or major in an internal project title do not determine the regulatory category. EMA reference.
Question 69 / 101
69. What is a Type IB variation in the EU?
Type IB covers specified minor changes outside Type IA, Type II and extensions. It involves notification before implementation and a defined waiting process under the applicable procedure. Confirm the current conditions, documentation and procedural dates for the specific change. EMA reference.
Question 70 / 101
70. Why is implementation timing part of a change assessment?
Technical readiness and regulatory permission are different milestones. A team may have completed manufacturing validation while a required regulatory step remains outstanding. The change plan should identify which markets can implement, on what basis and under whose documented authorisation.
Situational and workplace questions
Question 71 / 101
71. You find a product strength inconsistent between dossier sections. What would you do?
I would verify the discrepancy against the authorised source, preserve the original information and assess its immediate impact. I would pause affected work where necessary and involve the regulatory lead and relevant technical, quality or medical owner. I would document the clarification or correction and check whether other records or decisions are affected.
Question 72 / 101
72. Required information is missing from a dossier section and its approved source document. What next?
I would identify exactly what is missing and whether it prevents a safe or valid next step. I would seek the information from the authorised owner and document follow-up. I would not invent a value, and I would escalate any deadline or risk implication through the regulatory lead and relevant technical, quality or medical owner.
Question 73 / 101
73. You notice an inaccurate submitted document or unassessed product change. What is your priority?
I would follow the relevant immediate safety, quality or incident process and promptly involve the regulatory lead and relevant technical, quality or medical owner. I would preserve facts, restrict affected activity where required and avoid acting beyond my competence. Routine productivity targets would not justify delaying an urgent concern or bypassing a protective control.
Question 74 / 101
74. A deadline is close, but work on a dossier section and its approved source document remains incomplete. What would you do?
I would separate critical issues from lower-impact work, identify dependencies and communicate the realistic status early. With the regulatory lead and relevant technical, quality or medical owner, I would agree priorities and an authorised plan. I would not conceal incomplete checks or certify an unsupported result merely to meet the original deadline.
Question 75 / 101
75. A colleague asks you to skip a required check because the team is busy. How would you respond?
I would explain the purpose of the check and look for an authorised way to manage the workload. If a genuine alternative exists, I would seek appropriate approval; otherwise I would complete the requirement or escalate. The relevant escalation route here includes the regulatory lead and relevant technical, quality or medical owner.
Question 76 / 101
76. You discover the wrong version was used for a dossier section and its approved source document. What next?
I would identify the affected work, compare it with the correct baseline and inform the owner. I would assess whether any output was already shared or used, then follow the controlled correction process with the regulatory lead and relevant technical, quality or medical owner. I would preserve version history rather than overwrite evidence silently.
Question 77 / 101
77. You made an error in a record that has already been reviewed. How do you handle it?
I would acknowledge the error, establish its impact and notify the responsible reviewer promptly. I would correct through the approved process, keeping the original history and rationale. I would consider downstream outputs and inform the regulatory lead and relevant technical, quality or medical owner if the error affects safety, quality or an external decision.
Question 78 / 101
78. You accidentally send confidential information to the wrong recipient. What would you do?
I would stop further sharing and immediately follow the organisation's privacy or security incident process. I would notify the authorised incident team, preserve facts and follow their instructions on containment and communication. Deleting my sent message or privately asking for deletion would not replace incident reporting.
Question 79 / 101
79. The same problem, a product strength inconsistent between dossier sections, keeps recurring. How would you address it?
I would review examples to identify the common failure point, assess the impact and involve the process owner. I would consider instructions, training, system design and handoffs rather than assume individual carelessness. Corrective actions should have owners and an effectiveness check, not only a promise to be more careful.
Question 80 / 101
80. The approved system becomes unavailable during urgent work. What would you do?
I would preserve available work and follow the approved outage or continuity process. I would contact the support route and assess the deadline or safety impact with the regulatory lead and relevant technical, quality or medical owner. I would not move confidential information into a personal account or create an uncontrolled workaround to appear productive.
Question 81 / 101
81. Someone asks to use your login or grants you access beyond your role. How do you respond?
I would not share credentials or use unnecessary privileges. I would explain the accountability and confidentiality risks and request properly authorised access for the right person and task. Unexpected excessive access should be reported through the access-control process, with the facts recorded.
Question 82 / 101
82. Your manager gives you two assignments with overlapping deadlines. How would you prioritise?
I would compare risk, external commitments and dependencies, then explain the conflict with realistic time estimates. For this role I would consider critical document discrepancies, submission timeliness and overdue commitments alongside the immediate consequences. I would agree priorities and ownership rather than silently choose which commitment to miss.
Question 83 / 101
83. A reviewer disagrees with your technical conclusion. What would you do?
I would clarify the exact point, compare the evidence and applicable requirements, and explain my reasoning respectfully. If the issue remains unresolved, I would use the regulatory lead and relevant technical, quality or medical owner and document the decision appropriately. I would not change source facts to make the disagreement disappear.
Question 84 / 101
84. A source record contradicts a summary or dashboard. Which do you trust?
I would investigate the origin, version, definitions and transformations rather than blindly choose either. I would trace the summary back to authorised evidence and determine whether the mismatch affects other outputs. I would raise the issue through the regulatory lead and relevant technical, quality or medical owner and preserve the correction trail.
Question 85 / 101
85. How would you hand over unfinished work to another colleague?
I would record the current status, completed checks, source locations, unresolved issues and time-sensitive risks. I would identify the next owner and confirm understanding, using approved systems. In Regulatory Affairs, the handover should make the status of a dossier section and its approved source document unambiguous.
Question 86 / 101
86. A productivity metric improves while significant errors increase. What would you say?
I would check the metric definitions and investigate the quality trend before calling the change a success. Relevant measures include critical document discrepancies, submission timeliness and overdue commitments. I would present both speed and quality evidence, propose proportionate improvements and avoid treating hidden rework or safety risk as acceptable throughput.
Question 87 / 101
87. You are asked to perform an unfamiliar technical task without adequate training. What would you do?
I would explain my current competence and ask for the required training, supervision and authorisation. I could assist within an agreed safe scope while learning, but would not claim independent capability. I would involve the regulatory lead and relevant technical, quality or medical owner if the request could create a material risk.
Question 88 / 101
88. A stakeholder wants a more favourable answer than the evidence supports. How do you respond?
I would explain what the evidence does and does not show, identify uncertainty and offer an accurate alternative statement or further work. I would not alter results, remove inconvenient facts or invent justification. If pressure persists, I would use the appropriate quality, ethical or compliance escalation route.
Question 89 / 101
89. How would you explain a problem with a dossier section and its approved source document to a nontechnical colleague?
I would describe what is wrong, why it matters, what activity is affected and the decision needed in plain language. I would separate known facts from uncertainty and provide a clear owner and next step. I would avoid excessive jargon and unsupported accusations about who caused it.
Question 90 / 101
90. How would you respond to repeated critical feedback during training?
I would ask for concrete examples, compare them with the required standard and identify the main gap. I would agree a practice and review plan, use a focused checklist where appropriate and ask for reassessment. I would show progress with evidence rather than become defensive or hide difficult tasks.
How to handle an answer you do not know
Question 91 / 101
91. What should you say when you do not know an answer?
Say calmly: 'I do not know that detail confidently, and I do not want to guess. I understand …; I would verify the remaining point in the approved reference or ask the appropriate expert.' Explain any sound knowledge you do have. Do not turn uncertainty into a fabricated rule.
Question 92 / 101
92. What if you understand the concept but forget the exact term or number?
Explain the concept accurately and separate it from the detail you cannot recall. For example: 'I understand the sequence, but I would check the current specification before quoting a limit.' If invited to reason aloud, state your assumptions clearly rather than presenting an estimate as an approved value.
Question 93 / 101
93. How should you respond to an unclear or unfamiliar question?
Ask a focused clarification: 'Do you mean the clinical-trial process or the postmarketing process?' or 'Which product and market should I assume?' Then answer within that scope. Clarification is useful professional judgement, not an excuse to avoid a question you understand.
Question 94 / 101
94. What if the interviewer points out that your answer is wrong?
Listen, acknowledge the correction and restate the corrected understanding briefly. If your earlier answer depended on a different setting, explain that respectfully without arguing. A useful response is: 'Thank you; I mixed those concepts. In this setting the distinction is …'. Show that you can learn and correct errors.
Question 95 / 101
95. Would you guess when asked an unfamiliar safety-critical question?
No. Explain what action you would pause, which authorised person or reference you would consult and how you would preserve the record. In an interview, describe a safe decision process. Do not imply that you would independently change a patient treatment, release a batch or override a control to avoid admitting uncertainty.
Questions to ask the interviewer
Question 96 / 101
96. What should you say when asked Do you have any questions for us?
Prepare two or three relevant questions rather than asking all of them mechanically. A useful opening is: 'Yes, thank you. What would you most like the person in this role to achieve during the first three months?' Listen to the answer and ask one focused follow-up.
Question 97 / 101
97. How can you ask about training and supervision?
Ask: 'How is initial training organised, and how do you assess readiness for independent work?' This shows that you want to build competence responsibly. Avoid implying that you expect to work without required training or that a course certificate should exempt you from the employer's qualification process.
Question 98 / 101
98. How can you ask about the team's actual work?
Ask which responsibilities, systems, products or projects this position would support and how work is divided across the team. Use the department guide to make the question specific. Do not ask for confidential client names, patient information or unpublished company plans.
Question 99 / 101
99. What is a good question about performance expectations?
Ask: 'How do you balance quality, timeliness and workload when assessing this role?' Follow up on the review and feedback process. This gives a more useful picture than asking only how many items you must finish each day without considering their complexity or quality.
Question 100 / 101
100. When can you ask about shifts, compensation or practical conditions?
Ask the appropriate recruiter or interviewer at a suitable point, especially if a condition affects your availability. Be polite and specific about what you need to understand. You do not need to promise acceptance before receiving the terms, and there is no universal rule that candidates must never discuss pay.
Question 101 / 101
101. How should you close the interview?
Thank the interviewers, briefly reaffirm your interest and ask about the next stage and expected communication process. For example: 'Thank you for explaining the role. I am interested in the opportunity; could you share the next steps?' Avoid demanding an immediate decision or claiming qualifications you did not demonstrate.
Final preparation checklist
- Explain every technical claim on your resume with a truthful example.
- Revise the job description, required tools, terminology and role boundaries.
- Prepare two real examples of a challenge, learning or teamwork using Situation, Task, Action and Result.
- Practise admitting uncertainty clearly and describing how you would verify information.
- Prepare two or three thoughtful questions for the interviewer.
Official references and further study
- ICH: Common Technical Document
- FDA: Electronic Common Technical Document
- CDSCO: New Drugs and Clinical Trials Rules and amendments
- FDA: Types of drug applications
- FDA: Current Good Manufacturing Practice
- FDA: Q2(R2), Validation of Analytical Procedures
- ICH: Q1A(R2), Stability testing
- FDA: Drug Master Files
- EMA: Product-information requirements
- EMA: Type II variations